PMID- 2656341
OWN - NLM
STAT- MEDLINE
DCOM- 19890627
LR  - 20220408
IS  - 0012-1797 (Print)
IS  - 0012-1797 (Linking)
VI  - 38
IP  - 6
DP  - 1989 Jun
TI  - Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM 
      patients.
PG  - 723-9
AB  - To elucidate the value of using plasma 1,5-anhydro-D-glucitol (AG) as a marker of 
      glycemic control in diabetic patients, the relationship between the plasma 
      concentration of AG and glucosuria was examined in 152 patients with 
      non-insulin-dependent diabetes mellitus (NIDDM). After recovery from the 
      deterioration of glycemic control in NIDDM patients had started, AG began to 
      increase day by day. The recovery of plasma AG showed a constant linear increase 
      curve when excellent glycemic control was attained. The ordinary daily recovery 
      rate of plasma AG was estimated to be 0.3 microgram/ml, which was independent of 
      body weight, sex, age, the difference in treatment, the duration of diabetes, or 
      the level of plasma AG among NIDDM patients. This rate decreased according to the 
      increase in urinary glucose. When we calculated the decrease rate of plasma AG 
      (delta AG), assuming 0.3 microgram/day to be the maximum increase rate in a day, 
      we found a high correlation between delta AG and urinary glucose at almost all AG 
      levels except the normal range and observed that plasma AG (A) times urinary 
      glucose (G) was relatively constant. The formula A x G = 16 is a simple equation 
      for rough estimation of urinary glucose from the plasma AG concentration in a 
      stable glycemic-controlled NIDDM patient, and we call it the A.G index. The 
      plasma AG also correlated significantly with fasting plasma glucose (r = -.810) 
      and glycosylated hemoglobin (r = -.856) in the same stable glycemic-controlled 
      NIDDM patients. Based on these observations, we propose that plasma AG can serve 
      as a new marker that may provide sensitive and analytical information about 
      glycemic control.
FAU - Yamanouchi, T
AU  - Yamanouchi T
AD  - Second Department of Internal Medicine, University of Teikyo, Tokyo, Japan.
FAU - Minoda, S
AU  - Minoda S
FAU - Yabuuchi, M
AU  - Yabuuchi M
FAU - Akanuma, Y
AU  - Akanuma Y
FAU - Akanuma, H
AU  - Akanuma H
FAU - Miyashita, H
AU  - Miyashita H
FAU - Akaoka, I
AU  - Akaoka I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Deoxy Sugars)
RN  - 0 (Insulin)
RN  - 54BB3B7XMZ (1,5-anhydroglucitol)
RN  - 9G2MP84A8W (Deoxyglucose)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/*blood
MH  - Blood Glucose/analysis/*metabolism
MH  - Deoxy Sugars/*blood
MH  - Deoxyglucose/*blood
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy/urine
MH  - Fasting
MH  - Female
MH  - Glycosuria
MH  - Humans
MH  - Insulin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pregnancy
MH  - Pregnancy in Diabetics/blood
EDAT- 1989/06/01 00:00
MHDA- 1989/06/01 00:01
CRDT- 1989/06/01 00:00
PHST- 1989/06/01 00:00 [pubmed]
PHST- 1989/06/01 00:01 [medline]
PHST- 1989/06/01 00:00 [entrez]
AID - 10.2337/diab.38.6.723 [doi]
PST - ppublish
SO  - Diabetes. 1989 Jun;38(6):723-9. doi: 10.2337/diab.38.6.723.